evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

213 questions · 251 findings · 30 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 39 · 15.5%GRADE not reported 15 · 6%Very low 90 · 35.9%Low 56 · 22.3%Moderate 41 · 16.3%High 10 · 4%

Summary of Findings Table ‐ Low vs moderate‐high nasal continuous positive airway pressure levels

Bronchopulmonary dysplasia/chronic lung disease · health problem or population

It is very uncertain whether summary of Findings Table ‐ Low changes BPD, defined as supplemental oxygen or positive pressure support use… compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Low vs moderate‐high nasal continuous positive airway pressure levels

Combined outcome of mortality or BPD at 36 weeks' PMA · health problem or population

It is very uncertain whether summary of Findings Table ‐ Low changes death or BPD at 36 weeks' PMA compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher hypersensitivity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher pancreatitis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in osteonecrosis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher asparaginase‐associated toxicity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Overall survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in overall survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in event‐free survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Change in weight (kg) · overweight and obese participants without T2DM (weight‐reducing phase only)
2 findings from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Change in weight (kg) · overweight and obese participants with T2DM (weight‐reducing phase only)
2 findings from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only)

It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes weight loss of at least 5% at ≥ 12 months compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only)

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Constipation · overweight and obese participants with T2DM (weight‐reducing phase only)

It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes constipation at 3 to < 12 months compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Number of participants per group with weight loss of at least 5% at ≥ 12 months · overweight and obese participants without T2DM (weight‐reducing phase only)

It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes number of participants per group with weight loss of at least 5% at… compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase only)

The review found no eligible studies for this question.

1 finding from 1 review